Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study.
Doi H, Matsuo Y, Kishi N, Ogura M, Mitsuyoshi T, Ueki N, Ueki K, Fujii K, Sakamoto M, Atsuta T, Katagiri T, Sakamoto T, Narabayashi M, Ohtsu S, Fujishiro S, Kishi T, Mizowaki T; Kyoto Radiation Oncology Study Group (KROSG). Doi H, et al. Among authors: kishi n. Target Oncol. 2024 Nov 7. doi: 10.1007/s11523-024-01105-5. Online ahead of print. Target Oncol. 2024. PMID: 39511126
Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab.
Shintani T, Kishi N, Matsuo Y, Ogura M, Mitsuyoshi T, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Narabayashi M, Ishida Y, Sakamoto M, Fujishiro S, Katagiri T, Kim YH, Mizowaki T. Shintani T, et al. Among authors: kishi t, kishi n. Clin Lung Cancer. 2021 Sep;22(5):401-410. doi: 10.1016/j.cllc.2021.01.017. Epub 2021 Feb 4. Clin Lung Cancer. 2021. PMID: 33678582
Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer.
Kishi N, Matsuo Y, Shintani T, Ogura M, Mitsuyoshi T, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Ohtsu S, Katagiri T, Narabayashi M, Fujishiro S, Iizuka Y, Ozasa H, Hirai T, Mizowaki T; Kyoto Radiation Oncology Study Group (KROSG). Kishi N, et al. Among authors: kishi t. J Radiat Res. 2023 Jan 20;64(1):142-153. doi: 10.1093/jrr/rrac057. J Radiat Res. 2023. PMID: 36149029 Free PMC article.
Impact of Local Recurrence on Cause-Specific Death After Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: Dynamic Prediction Using Landmark Model.
Ueki K, Matsuo Y, Takeda A, Morita S, Taguri M, Kishi N, Hanazawa H, Tsurugai Y, Mizowaki T. Ueki K, et al. Among authors: kishi n. Int J Radiat Oncol Biol Phys. 2022 Apr 1;112(5):1135-1143. doi: 10.1016/j.ijrobp.2021.11.025. Epub 2021 Nov 26. Int J Radiat Oncol Biol Phys. 2022. PMID: 34838867
169 results